Oxygen Biotherapeutics, Inc. Reports Successful Completion of FDA Requested Immunocompetency Studies on Oxycyte®

Published: Jun 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), is a development stage biomedical company currently focused on developing its perfluorocarbon-based intravenous oxygen carrier, Oxycyte®, as a treatment for traumatic brain injury (TBI), stroke and other conditions where critical tissues are oxygen starved. Oxycyte is currently in Phase IIb clinical trials for TBI in Israel and Switzerland; however, the FDA has requested studies to explore the safety profile of Oxycyte with respect to immunocompetency as well as transient decreases in platelet numbers. The company announced today that with the successful completion of four important preclinical studies assessing Oxycyte’s potential effects on the immune system, OBI has moved several steps closer to addressing the questions posed by the FDA and demonstrating a favorable benefit to risk ratio for the product. These studies were funded as part of a $2.07 million cost reimbursement grant from the U.S. Army.

Help employers find you! Check out all the jobs and post your resume.

Back to news